Cymbalta receives FDA OK for depression maintenance

Observed by APhA and ASHP since 2023, bipartisan support has garnered to give pharmacy workforce suicide awareness its own federally recognized day.

Atogepant reduced migraine days during the perimenstrual period, positioning the medication as a potential first treatment option for the condition.

Chad Worz, PharmD, BCGP, FASCP, discusses the Main Street Pharmacy Access Act, a revolutionary pharmacy-focused bill moving through Congress.

Data show that commercially and Medicaid-insured children with chronic or immunocompromising conditions incur 2- to 3-fold higher costs.

Researchers assess the neurological outcomes of over 200,000 children exposed to COVID-19 before birth.

Results show consistent improvements in wakefulness, cataplexy, and quality of life with oveporexton for patients with narcolepsy.

Researchers assess the differences in out-of-pocket spending on brand name compared with generic medication.

Practical takeaways to improve real‑world clinic outcomes for PAINWeek 2026.